Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has counted Nvidia as an investor since 2023 when Jensen Huang's company invested ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial updates and Sanofi optioning a development candidate that triggered a US$10 ...

Recursion Pharmaceuticals reported Q3 2026 revenue of US$18.55 million and a net loss of US$119.04 million, while ...

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio SALT LAKE CITY, Nov. 09, 2023 ...

Scientists in Spain have implemented recursive least squares (RLS) algorithms for anomaly detection in PV systems and have found they can provide “more realistic and meaningful assessment” than ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...